Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626985 | 0.80 | PIK3CA (0.53) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL625391 | 0.76 | HASPIN (0.52) | HASPIN | |
| SCHEMBL625796 | 0.73 | PIK3CA (0.47) | PIK3CAPIK3CD | |
| SCHEMBL18193255 | 0.69 | PIK3CA (0.76) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL1309278 | 0.69 | PIK3CA (0.77) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL4075802 | 0.69 | AR (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL1310548 | 0.69 | ATR (0.58) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL624034 | 0.68 | LMNA (0.48) | — | |
| SCHEMBL10100419 | 0.67 | ROCK2 (0.71) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL19142657 | 0.67 | PIK3CA (0.65) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |